From Conjecture to Clarity
Supporting the Healthcare Industry
with Local Industry Knowledge
and Marketing Expertise
Our Offerings
Pharmaceutical Sales Forecast & Project Valuation
Our clients are industry leaders who would like to make well-informed decisions about entering markets.
We help clients understand the Japanese market, recognize threats and opportunities and provide a clear idea of the value of their innovation in Japan.
Our services include
- Forecasting models
- P&L assumptions
- Primary market research
- Competitive landscape
- Pricing Assumptions
Pharmaceutical Pricing Consultation
The pricing of pharmaceuticals always presents a challenge for companies seeking to expand their footprint in new markets.
We provide a full range of pricing and market access consultations from the planning stage to post-commercialization.
Our clients are able to develop fully integrated global pricing strategies to maximize the value of their product.
Our services include
- Forecasting Price Dynamics of New & Existing Products
- Consultation, Participation and Representation in the Official Price Negotiation Process
- In-Depth Interviews with MLHW Officials
Business Development Support
We support clients seeking to partner with Japanese companies.
e-Projection’s deep engagement in the industry network space differentiates us from any other vendor of the kind.
We are widely recognized for our knowledge of the local market and support the negation process by quantifying the value of the asset in a convincing manner.
We also have a network in China and can support those clients who additionally want to partner with Chinese companies.
Our services include
- Target Screening & Identification
- Approach to Initiate Communication
- Due Diligence
- Term Sheet Negotiation
- Approach to Initiate Communication
- Alliance Management
We help non-Japanese pharma/biotech companies understand and expand into the Japanese market.
Blog
-
2021.09.13blog-enPost event report: Online seminar “Update on the valuation of pharmaceuticals in the Covid-19 world”
e-Projection held an online seminar on September 10th, 2021. This seminar titled “Update on the valuation of pharmaceuticals in the Covid-19 world ” brought together more than 100 representatives from Japanese pharmaceutical companies. The speaker this time was our CEO, Toshi Nagate and he spoke about the valuation of development project from comprehensive aspect […]
-
2021.08.24blog-enNew Drugs Added to NHI Price List on August 12
The Central Social Insurance Medical Council (Chuikyo), an advisory board for the reimbursement system relating to public healthcare insurance, endorsed the listing of 23 new drugs with 15 ingredients at its general meeting on August 4. These new joined the NHI price list on August 12, including Chugai Pharmaceutical’s Evrysdi (risdiplam), which marks the first […]
-
2021.05.24blog-enTo Be, or Not to Be in Japan, That is the Problem
Consider involving Japan in your drug development program, and start thinking about it now Globalization in the pharmaceutical industry is an ongoing and never ending process due to the monotonically increasing desire of people all over the world to gain faster access to healthcare innovation, fueled by the tireless efforts of the drug manufacturers to […]
-
2021.05.13blog-ene-Projection is going to BIO Digital 2021!
We will be attending the BIO Digital 2021! Join us next June 10-11 and 14-17 in the virtual space this time, to discuss about your strategy to expand your business globally!! Now more than ever, the world is counting on us to come together to advance innovation and discovery.
-
2021.03.10blog-enTo the last drop
Allowing 7 shots per vial of Pfizer’s covid vaccine may wreak havoc to the already problematic Japanese immunization program Mottainai is one of the virtues of Japanese culture which means avoiding waste and making use of all that is available, especially in a country without significant natural resources. Yesterday, this sense of savings was taken […]
We help non-Japanese pharma/biotech companies understand and expand into the Japanese market.